EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antivirals to prepare for surges in influenza cases: an economic evaluation of baloxavir marboxil for the Netherlands

Simon van der Pol, Maarten J Postma, Cornelis Boersma

The European Journal of Health Economics · 2024

DOI: 10.1007/s10198-024-01683-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The European Journal of Health Economics, 2024. Verfasst von Simon van der Pol und 2 weiteren Autor:innen. Beteiligte Einrichtung: Health-Ecore, Utrechtseweg 60, 3704 HE, Zeist, The Netherlands. simonvanderpol@health-ecore.com. Hauptthemen laut MEDLINE: Influenza, Human, Cost-Benefit Analysis, Dibenzothiepins, Morpholines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Roche Nederland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

We perform a cost-effectiveness analysis (CEA) and budget impact analysis (BIA) of baloxavir marboxil compared to current care in the Netherlands for patients at risk of influenza-related complications, including patients with comorbidities and the elderly.

Methods

In the CEA, a decision tree model was developed to assess the cost-effectiveness of baloxavir marboxil for a cohort of 52-year-olds from a societal perspective. A lifetime horizon was taken by incorporating the quality-adjusted life expectancy. The BIA included different epidemiological scenarios, estimating different plausible epidemiological scenarios for seasonal influenza considering the whole Dutch population with an increased risk of influenza complications.

Results

The base-case ICER was estimated to be €8,300 per QALY. At the willingness-to-pay threshold of €20,000 per QALY, the probability of being cost effective was 58%. The base-case expected budget impact was €5.7 million on average per year, ranging from €1.5 million to €10.5 million based on the severity of the influenza epidemic and vaccine effectiveness.

Conclusion

In the Netherlands, baloxavir is a cost-effective treatment option for seasonal influenza, with a base-case ICER of €8,300 per QALY for the population aged 60 years and over and patients at high risk of influenza-related complications. For a large part, this ICER is driven by the reduction of the illness duration of influenza and productivity gains in the working population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza, HumanCost-Benefit AnalysisDibenzothiepinsMorpholinesAntiviral AgentsQuality-Adjusted Life YearsPyridonesTriazinesThiepinsHumansMiddle AgedNetherlandsMaleFemaleAgedOxazinesDecision TreesPyridines

Stichwörter der Autor:innen

AntiviralBaloxavirBudget impactCost effectivenessSeasonal influenza

Substanzen

baloxavirDibenzothiepinsMorpholinesAntiviral AgentsPyridonesTriazinesThiepinsOxazinesPyridines

Autor:innen und Institutionen

  • Health-Ecore, Utrechtseweg 60, 3704 HE, Zeist, The Netherlands. simonvanderpol@health-ecore.com.
  • Department of Health Sciences, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. simonvanderpol@health-ecore.com.
  • Health-Ecore, Utrechtseweg 60, 3704 HE, Zeist, The Netherlands.
  • Department of Health Sciences, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Department of Economics, Econometrics & Finance, University of Groningen, Groningen, The Netherlands.
  • Department of Management Sciences, Open University, Heerlen, The Netherlands.

Förderung

  • Roche Nederland

Zitieren

APA

van der Pol, S., Postma, M. J., & Boersma, C. (2024). Antivirals to prepare for surges in influenza cases: an economic evaluation of baloxavir marboxil for the Netherlands. The European Journal of Health Economics. https://doi.org/10.1007/s10198-024-01683-1

Vancouver

van der Pol S, Postma MJ, Boersma C. Antivirals to prepare for surges in influenza cases: an economic evaluation of baloxavir marboxil for the Netherlands. The European Journal of Health Economics. 2024. doi:10.1007/s10198-024-01683-1

BibTeX
@article{vanderPol2024,
  author = {van der Pol, Simon and Postma, Maarten J and Boersma, Cornelis},
  title = {Antivirals to prepare for surges in influenza cases: an economic evaluation of baloxavir marboxil for the Netherlands},
  journal = {The European Journal of Health Economics},
  year = {2024},
  doi = {10.1007/s10198-024-01683-1}
}
Kostenlos starten →